• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ann Lab Med . Combination of a SARS-CoV-2 IgG Assay and RT-PCR for Improved COVID-19 Diagnosis

tetano

Editor, Senior Moderator
Ann Lab Med


. 2021 Nov 1;41(6):568-576.
doi: 10.3343/alm.2021.41.6.568.
Combination of a SARS-CoV-2 IgG Assay and RT-PCR for Improved COVID-19 Diagnosis


Kotaro Aoki[SUP] 1 [/SUP], Kunitomo Takai[SUP] 2 [/SUP], Tatsuya Nagasawa[SUP] 1 [/SUP], Katsuhito Kashiwagi[SUP] 3 [/SUP], Nobuaki Mori[SUP] 4 [/SUP], Keiji Matsubayashi[SUP] 5 [/SUP], Masahiro Satake[SUP] 5 [/SUP], Ippei Tanaka[SUP] 2 [/SUP], Nanae Kodama[SUP] 6 [/SUP], Takahiro Shimodaira[SUP] 6 [/SUP], Yoshikazu Ishii[SUP] 1 [/SUP], Taito Miyazaki[SUP] 3 [/SUP], Toshiaki Ishii[SUP] 6 [/SUP], Toshisuke Morita[SUP] 7 [/SUP], Toru Yoshimura[SUP] 2 [/SUP], Kazuhiro Tateda[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is generally diagnosed by reverse transcription (RT)-PCR or serological assays. The SARS-CoV-2 viral load decreases a few days after symptom onset. Thus, the RT-PCR sensitivity peaks at three days after symptom onset (approximately 80%). We evaluated the performance of the ARCHITECT[SUP]®[/SUP] SARS-CoV-2 IgG assay (henceforth termed IgG assay; Abbott Laboratories, Lake County, IL, USA), and the combination of RT-PCR and the IgG assay for COVID-19 diagnosis.
Methods: In this retrospective study, 206 samples from 70 COVID-19 cases at two hospitals in Tokyo that were positive using RT-PCR were used to analyze the diagnostic sensitivity. RT-PCR-negative (N=166), COVID-19-unrelated (N=418), and Japanese Red Cross Society (N=100) samples were used to evaluate specificity.
Results: Sensitivity increased daily after symptom onset and exceeded 84.4% after 10 days. Specificity ranged from 98.2% to 100% for samples from the three case groups. Seroconversion was confirmed from 9 to 20 days after symptom onset in 18 out of 32 COVID-19 cases with multiple samples and from another case with a positive result in the IgG assay for the first available sample.
Conclusions: The combination of RT-PCR and IgG assay improves the robustness of laboratory diagnostics by compensating for the limitations of each method.

Keywords: ARCHITECT®; COVID-19; Immunoassay; Reverse transcription (RT)-PCR; SARS-CoV-2 IgG; Sensitivity; Specificity.
 
Back
Top Bottom